Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lingdolinurad - Atom Bioscience

Next Previous
Search
Drug Profile

Lingdolinurad - Atom Bioscience

Alternative Names: ABP-671

Latest Information Update: 09 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atom Bioscience
  • Class Antigouts; Antirheumatics; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gout
  • Phase II Hyperuricaemia

Most Recent Events

  • 03 Dec 2024 Atom Therapeutics and China Medical System Holdings enter into an exclusive commercialization agreement for Lingdolinurad in China, Hongkong and Macau
  • 05 Sep 2024 Atom Bioscience terminates a Phase-II/III extension clinical trials in Gout in Taiwan, Georgia, Guatemala, Australia and USA(PO) due to redesign of clinical development program for ABP-671 (NCT06276556)
  • 24 Apr 2024 Atom Bioscience initiates enrollment in phase II/III trial in Gout in USA (PO) (NCT05818085)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top